Shares in Egalet Corp. (NSDQ:EGLT) soared this morning in pre-market activity after the company reported that its abuse-deterrent, extended-release oxycodone candidate met the primary endpoint of a Phase III pain relief trial.
The Wayne, Penn.-based company compared the efficacy and safety of its product to a placebo in opioid-experienced and opioid-naïve patients with moderate-to-severe chronic low back pain.
Get the full story at our sister site, Drug Delivery Business News.
The post Egalet’s extended-release, abuse-deterrent opioid succeeds in Ph3 trial appeared first on MassDevice.
from MassDevice http://ift.tt/2nbq4Nr
Cap comentari:
Publica un comentari a l'entrada